Results of treatment of post vitrectomy vitreous hemorrhage in patients with proliferative diabetic retinopathy with the use of ranibizumab
DOI:
https://doi.org/10.31288/oftalmolzh201522226Keywords:
proliferative diabetic retinopathy, vitrektomiya, hemophthalmus, ranibizumabAbstract
Introduction. Post vitrectomy vitreous hemorrhage is the main cause of failure in vitreous surgery of proliferative diabetic retinopathy, the rate of this complication is 25–75 % of cases.
Aim of the study. To compare the efficiency of application of the of fluid gas exchange in the treatment of post vitrectomy vitreous hemorrhage in patients with PDRP with and without use of ranibizumab.
Materials and methods. There were analyzed the results of treatment of post vitrectomy vitreous hemorrhage in 78 patients (78 eye) with proliferative diabetic retinopathy by the fluid gas exchange with the use of 20 % of the gas — air mixture of perfluoropropane. In 28 patients (28 eyes) — main group additionally in the vitreous cavity was introduced 0,5 mg of ranibizumab.
Results. 2 months after the treatment there were no significant differences (?2=0,73; p=0,39) in achievement of transparency of vitreous cavity with the use of ranibizumab and without it. After 6 months in the group with additional use of ranibizumab transparency of vitreous content was reached in 96,4 % of cases, and without it in 92,0 % (?2 = 0,59; р = 0,44), but the recurrence rate of vitreous hemorrhage in patients without use of ranibizumab was significantly higher– 11 eyes (22,0 %) against 1 (3,6 %) (?2 = 4,68; р = 0,03).
Conclusion. Fluid gas exchange with 20 % of the gas — air mixture of perfluoropropane with additional introduction in vitreuos cavity of ranibizumab is the most effective treatment of post vitrectomy vitreous hemorrhage in patients of proliferative diabetic retinopathy and can be widely used.
References
Nosov SV. Treatment strategy for later post vitrectomy hemophthalmus in diabetic patients. Oftalmokhirurgiia. 2011;3:53-6. In Russian.
Pogorelyi DN, Putiyenko AA. The results of substitution gas tamponade in the treatment of unabsorbable hemophthalmus after vitrectomy in patients with proliferative diabetic retinopathy. Problemy ekologichnoi ta medichnoi genetiki I klinichnoi imunologii: a collection of papers. 2012;2(110): 484-91. In Russian.
Putiyenko AA, Pogorelyi DN. Cytokine profile of blood and vitreous fluid of patients with proliferative diabetic retinopathy with hemophthalmia after vitrectomy. Kazanskii med. zhurn. 2013;94(1):26-30. In Russian. https://doi.org/10.17816/KMJ1764
Sdobnikova SV, Mazurina NK, Stolyarenko GYe, Fedorov FF, Chekmareva IA, Kochetkova EA. Modern approach to the treatment of proliferative diabetic retinopathy. Russkii Med. Zhurnal. 2002;3(3):99-105. In Russian.
Abbate M, Cravedi P, Iliev I. Prevention and treatment of diabetic retinopathy: evidence from clinical trials and perspectives. Curr Diabetes Rev. 2011;7(3):190-200. https://doi.org/10.2174/157339911795843168
Entezari M, Ramezani A, Ahmadieh H. Cryotherapy of sclerotomy sites for prevention of late post - vitrectomy diabetic hemorrhage: a randomized clinical trial. Graefes. Arch Clin Exp Ophthalmol. 2010;248:1-19. https://doi.org/10.1007/s00417-009-1182-7
G?nd?z K, Bakri SJ. Management of proliferative diabetic retinopathy. Compr. Ophthalmol Update. 2007;8(5):245-56.
Koutsandrea CN, Apostolopoulos MN, Chatzoulis DZ et al. Hemostatic effects of SF6 after diabetic vitrectomy for vitreous hemorrhage. Acta Ophthalmol Scand. 2001;79(1):34-8. https://doi.org/10.1034/j.1600-0420.2001.079001034.x
Neely KA, Scroggs KA, McCuen BW. Peripheral retinal cryotherapy for postvitrectomy diabetic vitreous hemorrhage in phakic eyes. Am. J. Ophthalmol. 1998;126(1):82-90. https://doi.org/10.1016/S0002-9394(98)00066-X
Sato T, Morita S, Bando H. Early vitreous hemorrhage after vitrectomy with preoperative intravitreal bevacizumab for proliferative diabetic retinopathy. Middle East Afr J Ophthalmol. 2013;20(1):51-5. https://doi.org/10.4103/0974-9233.106387
Steel DH, Connor A, Habib MS. Entry site treatment to prevent late recurrent postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy. Br. J. Ophthalmol. 2010;94:1219-25. https://doi.org/10.1136/bjo.2009.170126
Steel D H, Habib MS, Park S, Hildreth AJ, Owen RI. Entry site neovascularization and vitreous cavity hemorrhage after diabetic vitrectomy. The predictive value of inner sclerostomy site ultrasonography. Ophthalmology. 2008; 115:525-32. https://doi.org/10.1016/j.ophtha.2007.08.034
Tolentino F, Cajita V, Gancayco T, Skates S. Vitreous hemorrhage after closed vitrectomy for proliferative diabetic retinopathy / F. TolentinoOphthalmology. 1989;96(10):1495-500. https://doi.org/10.1016/S0161-6420(89)32700-X
Yang CM, Yeh PT, Yang CH. Intravitreal long - acting gas in the prevention of early postoperative vitreous hemorrhage in diabetic vitrectomy. Ophthalmology. 2007;114(4):710-5. https://doi.org/10.1016/j.ophtha.2006.07.047
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 А. А. Путиенко, Али Элхадж, Д. Н. Погорелый
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) that allows users to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author as long as they cite the source.
COPYRIGHT NOTICE
Authors who publish in this journal agree to the following terms:
- Authors hold copyright immediately after publication of their works and retain publishing rights without any restrictions.
- The copyright commencement date complies the publication date of the issue, where the article is included in.
DEPOSIT POLICY
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) during the editorial process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work with an acknowledgement of its initial publication in this journal.
- Post-print (post-refereeing manuscript version) and publisher's PDF-version self-archiving is allowed.
- Archiving the pre-print (pre-refereeing manuscript version) not allowed.
